Skip to NavigationSkip to content


US DoJ launch investigation into Acadia Pharmaceuticals

Image Credit: Another Believer

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia Pharmaceuticals in relation to Nuplazid, a psychosis drug for those with Parkinson’s disease.

Nuplazid, an antipsychotic for those suffering from hallucinations and delusions with Parkinson’s, received FDA approval in 2016.

FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) for the treatment of psychosis related to Parkinson’s disease.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches